Efficacy and safety of follow‐up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12‐month study

Ingenol mebutate (IngMeb) is a novel patient‐applied topical field therapy for actinic keratosis.

[1]  L. Torezan,et al.  Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5‐fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  R. Dellavalle,et al.  Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. , 2015, JAMA dermatology.

[3]  A. Ariza,et al.  Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  S. Shumack,et al.  Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis. , 2014, The Journal of clinical and aesthetic dermatology.

[5]  Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis. , 2014, The Journal of clinical and aesthetic dermatology.

[6]  B. Berman,et al.  Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. , 2014, Journal of drugs in dermatology : JDD.

[7]  Ellen S. Marmur,et al.  A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate , 2014, Dermatology and Therapy.

[8]  S. Vegter,et al.  A Network Meta-Analysis of the Relative Efficacy of Treatments for Actinic Keratosis of the Face or Scalp in Europe , 2014, PloS one.

[9]  N. Swanson,et al.  Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. , 2014, Journal of drugs in dermatology : JDD.

[10]  N. Swanson,et al.  Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. , 2014, Journal of drugs in dermatology : JDD.

[11]  A. Carr,et al.  Non-adherence to topical treatments for actinic keratosis , 2013, Patient preference and adherence.

[12]  E. Stockfleth,et al.  The natural history of actinic keratosis: a systematic review , 2013, The British journal of dermatology.

[13]  M. Lebwohl,et al.  Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. , 2013, JAMA dermatology.

[14]  L. Mullenders,et al.  Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients , 2013, BMC Cancer.

[15]  A. Suhrbier,et al.  Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice , 2012, Archives of Dermatological Research.

[16]  A. Suhrbier,et al.  Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. , 2012, The Journal of investigative dermatology.

[17]  I. Zalaudek,et al.  Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. , 2012, Journal of the American Academy of Dermatology.

[18]  Neil Swanson,et al.  Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.

[19]  S. Tyring,et al.  Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. , 2012, Journal of the American Academy of Dermatology.

[20]  R. S. Padilla,et al.  Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. , 2010, Archives of dermatology.

[21]  J. Ortonne,et al.  Management of field change in actinic keratosis , 2007, The British journal of dermatology.

[22]  J. Eberle,et al.  Low prevalence of p53, p16INK4a and Ha‐ras tumour‐specific mutations in low‐graded actinic keratosis , 2007, The British journal of dermatology.

[23]  S. Salasche,et al.  Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. , 2002, Journal of the American Academy of Dermatology.

[24]  D. Czarnecki,et al.  The Majority of Cutaneous Squamous Cell Carcinomas Arise in Actinic Keratoses , 2002, Journal of cutaneous medicine and surgery.

[25]  D. Alberts,et al.  Chemoprevention of human skin cancer. , 2002, Critical reviews in oncology/hematology.

[26]  A. Green,et al.  High incidence and regression rates of solar keratoses in a queensland community. , 2000, The Journal of investigative dermatology.

[27]  F. Flowers,et al.  Frequency of pre‐existing actinic keratosis in cutaneous squamous cell carcinoma , 1998, International journal of dermatology.

[28]  C. Cockerell,et al.  Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. , 2013, Journal of the American Academy of Dermatology.

[29]  R. Ceilley,et al.  Current issues in the management of actinic keratosis. , 2013, Journal of the American Academy of Dermatology.

[30]  J. Q. Rosso,et al.  Actinic Keratoses: Natural History and Risk of Malignant Transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial , 2010 .

[31]  B. Berman.  Clinical, Cosmetic and Investigational Dermatology New Developments in the Treatment of Actinic Keratosis: Focus on Ingenol Mebutate Gel , 2022 .